secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-10-08T12:38:38+00:00
Accession:  0001628280-26-065408
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Vir Biotechnology's VIR-5500 wins FDA Fast Track in late-line mCRPC; Phase 3 set for 2027
--------------------------------------------------------------------------------

- FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer (mCRPC).
- VIR-5500 is co-developed with Astellas Pharma Inc. under a global strategic collaboration; pivotal Phase 3 development is anticipated to begin in 2027.
- Phase 1 study spans six dose-expansion cohorts: monotherapy in taxane-naive, radioligand therapy-naive and radioligand-exposed mCRPC.
- Combination cohorts test VIR-5500 with enzalutamide or docetaxel in early-line mCRPC, and with darolutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
- Earlier 2026 Phase 1 data showed VIR-5500 was generally well tolerated with promising anti-tumor activity in mCRPC patients, per CEO Marianne De Backer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026065408/0001628280-26-065408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026065408/vir-20261008.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-065408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer